Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 17/20 | 0.43 |
| ▸ | JAK1 | P23458 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25297236 | 0.77 | ABL1 (0.40) | JAK1ALDH1A1TP53 | |
| SCHEMBL30198115 | 0.77 | ABL1 (0.40) | JAK1ALDH1A1TP53 | |
| SCHEMBL16428243 | 0.77 | NQO2 (0.37) | JAK1ALDH1A1TP53 | |
| SCHEMBL29187958 | 0.74 | ABL1 (0.44) | JAK1ALDH1A1TP53 | |
| SCHEMBL30159109 | 0.74 | POLB (0.43) | JAK1ALDH1A1TP53 | |
| SCHEMBL29187908 | 0.74 | POLB (0.43) | JAK1ALDH1A1TP53 | |
| SCHEMBL30159073 | 0.74 | ABL1 (0.44) | JAK1ALDH1A1TP53 | |
| SCHEMBL25262955 | 0.73 | ACHE (0.44) | OPRK1ALDH1A1 | |
| SCHEMBL30258024 | 0.73 | ACHE (0.44) | OPRK1ALDH1A1 | |
| SCHEMBL23243241 | 0.73 | MAP4K1 (0.46) | OPRK1JAK1ALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227411-A1 | Benzimidazole Derivatives | HOFFMANN-LA ROCHE INC. (US) | 2023-07-20 | — | — | US | disclosed |
| EP-4136078-A1 | BENZIMIDAZOLE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2023-02-22 | — | — | EP | disclosed |
| CN-115443268-A | Benzimidazole derivatives | 豪夫迈·罗氏有限公司 | 2022-12-06 | — | — | CN | disclosed |
| WO-2021209485-A1 | BENZIMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2021-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227411-A1 | Benzimidazole Derivatives | CCNI, CCNB3, CYP3A43 | OPRK1 767/4885JAK1 1095/4885ALDH1A1 180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.